Zhong Ji Longevity Science Forecasts Loss in 2024

MT NewswiresMar 20 20:34

According to the profit warning, ZHONG JI LS (00767.HK) expects to incur a loss of at least 32 million yuan for the entire year.

ZHONG JI LS (00767.HK) issued a profit warning, anticipating a net loss attributable to shareholders of the company in the range of 32 million to 35 million yuan for the fiscal year 2024, compared to a profit of 2.3 million yuan last year. This is mainly due to non-recurring legal and service fees of approximately 20.4 million yuan incurred from the collection of a long-term outstanding loan from a subsidiary; significant marketing costs related to the MNM supplements for the ZHONG JI LS business in mainland China; and substantial restructuring costs associated with the withdrawal of the MNM dietary supplements retail sector and other health product lines.

AASTOCKSMar 20 01:32

ZHONG JI LS (00767) issues a profit warning, expecting a net loss of approximately 32 million to 35 million Hong Kong dollars for the fiscal year 2024.

ZHONG JI LS (00767) announced that the group expects to achieve a net loss of approximately 32 million in the fiscal year 2024...

Zhitong FinanceMar 19 21:16

ZHONG JI LS: PROFIT WARNING

HKEXMar 19 21:04 · Announcements

ZHONG JI LS (00767.HK) will hold a Board of Directors meeting on March 28 to approve the annual performance.

On March 18, Glonghui announced that ZHONG JI LS (00767.HK) will hold a Board of Directors meeting on March 28, 2025, to approve the announcement of the company's and its subsidiaries' annual performance for the year ending December 31, 2024, and to consider the proposal for the distribution of a final dividend (if any).

Gelonghui FinanceMar 18 19:46

Hong Kong Stock Announcement to Explore Opportunities | Aimei Vaccine: mRNA RSV vaccine shows significantly higher humoral immunity and cellular immunity than internationally marketed products, and has applied for clinical trials in the USA.

HBM HOLDINGS-B (02142): The HBM9378/SKB378 for the treatment of chronic obstructive pulmonary disease has been approved for IND permission by the NMPA; HENLIUS (02696): The European Commission has approved the use of Surulimab injection in combination with chemotherapy for first-line treatment in adult patients with extensive-stage small cell lung cancer.

Zhitong FinanceFeb 5 22:53